

# HemeScreen® BCR/ABL1 Panel



## Expect More From Your Testing


Precipio uses HemeScreen technology to expand beyond standard BCR/ABL1 breakpoint testing for more **comprehensive diagnostics** in a **simple workflow** commanding **higher reimbursements**.

### Broader Coverage




**4 Breakpoint coverage** in a single reagent set to more broadly assess initial cases and better monitor changes in breakpoint expression

### Faster TAT



Labor-efficient workflows and small batching ability enables **1-2 day TAT** on most cases (**66%**). p210 positive cases reflexed to qPCR

### Lower qPCR Reagent Costs



**66% Reduction** in qPCR reagent costs by using HemeScreen technology

### Higher Reimbursement



**71% higher reimbursement** by testing 4 clinically relevant<sup>1</sup> breakpoints

### HemeScreen Assay Performance: 5X lower Limit of Detection

Precipio developed the HemeScreen BCR/ABL1 assay for our own clinical lab, optimized to exceed today's performance standards to ensure we provide the most accurate diagnosis for each patient. HemeScreen's 5X lower Limit of Detection compared to other assays means we offer the best in class MRD status assessment.

1: <https://tumourclassification.iarc.who.int/chaptercontent/63/10>

The above is based on Precipio clinical lab's internal data.

For more information please contact:

contact@precipiodx.com | www.precipiodx.com | Tel: +1.203.787.7888

